Epstein-Barr virus (EBV) oriP and the EBV nuclear antigen 1 (EBNA-1) protein allow persistence of EBVbased episomes. A nuclear matrix attachment region (MAR) spans oriP and the adjacent region of the EBV genome containing the EBV-expressed RNAs. Here, we show that episomes with the MAR are retained significantly more efficiently in EBV-positive B cells than episomes containing oriP alone.
genes may play a role in blocking cellular apoptosis, thereby promoting oncogenicity in BL (8) .
We have previously shown that EBV episomes can carry large genomic DNA inserts for prolonged periods in cell culture (16) and that genomic DNA transgenes can be functionally expressed from these episomes in mammalian cell culture (17) . Here, we investigate the functional significance of the MAR that spans oriP and includes the EBER genes, with a view to improved understanding of EBV episomal systems.
We constructed a series of mini-EBV replicons containing a 60-kb human genomic DNA insert and three variants of oriP (Fig. 1) . The mini-EBV plasmid amplicons (pmEBV) contained oriP, defined as positions 7338 to 9520 in the B95-8 strain (19, 20) . The amplicon pmEBV-EBER ( Fig. 1) contains EBV DNA from position 4948 to 9520, which includes oriP and the entire region previously defined as attached to the nuclear matrix. pmEBV-⌬DS is the same as pmEBV with the DS removed by excision of the EcoRV/HpaI 140-bp fragment. All plasmids also contained the EBV terminal repeats, oriLyt and an EBNA-1 expression cassette. To allow the tracking of the episome in mammalian cells, expression cassettes for enhanced green fluorescent protein (GFP) and hygromycin phosphotransferase were included.
The vectors were transfected into HH514 cells, a BL cell line that contains a nontransforming strain of EBV (13), using a peptide-Lipofectin reagent described elsewhere (2) . Transfected cells were selected with hygromycin B, and several clonal cell lines were isolated by dilution cloning: three carried pmEBV (HHmE-C1-3), three carried pmEBV-EBER (HHmE-EBER-C1-3), and one carried pmEBV-⌬DS (HHmE⌬DS-C1). DNA was isolated from these lines and was transformed into bacteria to recover the episome, using protocols described elsewhere (16) . All episomes rescued from all of the HHmE and HHmE-EBER cell lines were identical to the original plasmid. Five of six rescued episomes analyzed from HHmE⌬DS-C1 were unaltered, but one appeared to have undergone a deletion of part of its genomic DNA insert (results not shown). Copy number analysis by quantitative Southern blotting of genomic DNA from the human cell lines (17) indicated that they carried between 35 and 64 episomes per cell ( Table 1 ). The presence of the EBV genome in HH514 cells prevented the direct detection of EBER genes attributable to the introduced episomes in this cell line. However, EBER expression was detected from the pmEBV-EBER construct by Northern blot analysis, following transfection of the plasmid into EBV-negative 293 cells (not shown).
We then grew each cell line in both the presence and absence of hygromycin B selection. Every 5 days, flow cytometry was used to measure the proportion of cells expressing GFP and hence carrying the episome (Fig. 2) . The loss of GFP expression allowed us to follow the loss of episome and thus to quantify episome retention efficiency. In these experiments, we assume that green fluorescence equates to episomal status because we did not observe a plateau phenomenon or reduction in fluorescence typical of cells in which an integration event has significantly outgrown the population (16) . A cell was defined as green if it fluoresced more strongly than 99.5% of untransfected HH514 cells. The loss of green fluorescence of a cell only begins to occur once it has lost all episomes and when preexisting GFP protein degrades, so a change in their green status will lag somewhat behind the loss of the episome. To model this, the data was fitted with a line of the form y ϭ ae b(xϪc) where y is the number of generations and x is the percentage of cells which remain green. The constant a is the percentage of green cells at the start of the relaxation, b is the rate of episome loss in terms of the proportion of cells losing the episome each generation, and c is the lag time in generations.
The results shown in Fig. 2 and Table 1 indicate that episomes containing the MAR are retained significantly more efficiently than those lacking the EBER genes (P ϭ 0.0007 by the Student t test), despite the slightly lower episome copy number of the pmEBV-EBER construct. Thus, the half-life of episome-carrying cells in the absence of selective pressure almost doubles, from approximately 25 to 49 cell divisions (31 to 61 days). The episome in which the DS was deleted from oriP was lost at a rate similar to those retaining a full oriP. These latter data are consistent with recent results for a recombinant EBV deleted for the DS, which was lost at the same rate as virus with wild-type oriP (12). We have not tested the effect of deletion of the DS in the presence of the MAR.
Unexpectedly, the HHmE-EBER cell lines consistently expressed a higher level of GFP (reflected by the value of a) ( Table 1) , although it does not influence the calculations of episome retention. This may be mediated by the transcription factor binding sequences in the regulatory elements of the EBER genes (4), either acting alone or in conjunction with FR. It is unlikely that the EBER transcripts are directly responsible for this effect, as the HH514 cells express EBER genes from their native virus in all of the cell lines studied. It may be interesting to assess whether a similar effect is observed for EBV promoters that are activated by FR, such as the EBNA genes' promoter, pC, and the latent membrane protein 1 promoter.
This study has not established whether the improved retention of oriP-MAR requires EBV in trans. Since the EBER genes are expressed by the EBV genome in HH514 cells in all the cell lines studied, we can conclude that the presence of the EBER genes (or nearby DNA elements) in cis significantly improves the retention of EBV-based episomes. These elements may or may not require the presence of the EBER RNAs themselves. Further study of these episomes in an EBV-negative cell line could address this question. Alternatively, EBER genes minimally mutated to abrogate expression (18) could be useful reagents to probe their role in episome retention.
A recent report has shown that the EBV region spanning positions 6400 to 8300 exhibits an extremely high sensitivity to micrococcal nuclease, indicating either an unusual nucleosome structure or a complete absence of nucleosomes (18) . This region includes the FR and both EBER genes (but not the DS) and is entirely contained within both the previously defined MAR (6) and the region mediating improved episome retention described herein. Taken together, these data suggest that the region of the EBV genome covering the EBER genes and the FR adopts an unusual structure that promotes association with the nuclear matrix. This may be mechanistically related to metaphase chromosome association, which is critical in episome maintenance (5). Table 1 .
Recent results from Leight and Sugden (11) reinforce this hypothesis. The authors found that a stochastic, epigenetic event is required for efficient partitioning of oriP plasmids (11), for which they invoke a mechanism involving chromatin configuration. Given that sites of transcriptional regulation and origins of replication are often clustered around cellular and viral MARs (6), incorporation of the point mutations used by Wensing et al. (18) to modulate the EBER promoter in our vector would be an elegant test of this hypothesis. Further elucidation of the cis and trans elements that promote these effects promises to enhance our understanding of episomal maintenance, nuclear matrix attachment, and EBV nucleosome organization and also holds the promise of improved episomal gene transfer vectors.
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